Skip to main content
Top
Published in: Drug Safety 3/2017

01-03-2017 | Original Research Article

Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France

Authors: Marine Auffret, Julien Labreuche, Alain Duhamel, Sylvie Deheul, Olivier Cottencin, Régis Bordet, Sophie Gautier, Benjamin Rolland

Published in: Drug Safety | Issue 3/2017

Login to get access

Abstract

Introduction

Off-label prescribing (OLP) may raise serious safety concerns that traditional spontaneous reporting of adverse drug reactions (ADRs) may not identify in a timely manner. In France, the ‘Multidisciplinary Consultation Service for Off-Label Prescribing in Addiction Medicine’ (CAMTEA) is a proactive regional system established to identify ADRs associated with the OLP of baclofen for alcohol dependence.

Objective

The aim was to demonstrate, using the French pharmacovigilance database (FPVD), that CAMTEA allowed for the reporting of a substantial amount of ADRs, comparable in nature to those provided via spontaneous reporting.

Method

The 2012–2013 FPVD notifications associated with baclofen OLP were extracted. The ten most frequent types of ADRs among ‘serious’ and ‘non-serious’ reports were listed. The frequency of each type of ADR was compared between CAMTEA and spontaneous reporting, and the magnitudes of the differences were assessed using standardized differences.

Results

A total of 428 baclofen reports (1043 ADRs) were identified, among which 221 (51.64%) originated from CAMTEA. The ten most frequent ADRs in ‘serious’ reports were (1) confusion (17.3%), (2) seizures (11.5%), (3) drowsiness/sedation (11.5%), (4) agitation (10.9%), (5) coma (9.6%), (6) hallucinations (7.7%), (7) falls (7.1%), (8) behavioral disorders (5.8%), (9) withdrawal syndrome (5.1%), and (10) space–time disorientation (5.1%). A standardized difference of <0.2 was identified for six out of the ten most frequent ‘serious’ ADRs, and eight of the ten ‘non-serious’ ADRs.

Conclusion

A proactive regional pharmacovigilance system could collect a substantial amount of safety data on a specific OLP practice. The profile of the ADRs collected was similar to that seen in the nationwide spontaneous reporting system.
Literature
1.
go back to reference Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021–6.CrossRefPubMed Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021–6.CrossRefPubMed
2.
go back to reference Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics. 2009;37(476–86):396. Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics. 2009;37(476–86):396.
3.
go back to reference Dal Pan GJ. Monitoring the safety of medicines used off-label. Clin Pharmacol Ther. 2012;91:787–95.CrossRef Dal Pan GJ. Monitoring the safety of medicines used off-label. Clin Pharmacol Ther. 2012;91:787–95.CrossRef
5.
go back to reference Rolland B, Bordet R, Cottencin O. Alcohol-dependence: the current French craze for baclofen. Addiction. 2012;107:848–9.CrossRefPubMed Rolland B, Bordet R, Cottencin O. Alcohol-dependence: the current French craze for baclofen. Addiction. 2012;107:848–9.CrossRefPubMed
8.
go back to reference Rolland B, Deheul S, Danel T, Bordet R, Cottencin O. A system of prescriptions without drug approval: example of baclofen. Therapie. 2010;65:511–8.CrossRefPubMed Rolland B, Deheul S, Danel T, Bordet R, Cottencin O. A system of prescriptions without drug approval: example of baclofen. Therapie. 2010;65:511–8.CrossRefPubMed
9.
go back to reference Rolland B, Deheul S, Danel T, Bence C, Blanquart M-C, Bonord A, et al. Temporary recommendation for use on off-label baclofen: viewpoint of prescribers of the CAMTEA system. Therapie. 2015;70:235–8.CrossRef Rolland B, Deheul S, Danel T, Bence C, Blanquart M-C, Bonord A, et al. Temporary recommendation for use on off-label baclofen: viewpoint of prescribers of the CAMTEA system. Therapie. 2015;70:235–8.CrossRef
11.
go back to reference Chaignot C, Weill A, Ricordeau P, Alla F. Use in France of baclofen for alcohol dependence from 2007 to 2013: cohort study based on the databases SNIIRAM and PMSI. Therapie. 2015;70:443–53.CrossRefPubMed Chaignot C, Weill A, Ricordeau P, Alla F. Use in France of baclofen for alcohol dependence from 2007 to 2013: cohort study based on the databases SNIIRAM and PMSI. Therapie. 2015;70:443–53.CrossRefPubMed
13.
go back to reference Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJ, Aronson JK, et al. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol. 1996;42:423–9.CrossRefPubMedPubMedCentral Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJ, Aronson JK, et al. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol. 1996;42:423–9.CrossRefPubMedPubMedCentral
14.
go back to reference Rolland B, Deheul S, Danel T, Bordet R, Cottencin O. A case of de novo seizures following a probable interaction of high-dose baclofen with alcohol. Alcohol Alcohol. 2012;47:577–80.CrossRefPubMed Rolland B, Deheul S, Danel T, Bordet R, Cottencin O. A case of de novo seizures following a probable interaction of high-dose baclofen with alcohol. Alcohol Alcohol. 2012;47:577–80.CrossRefPubMed
15.
go back to reference Rolland B, Labreuche J, Duhamel A, Deheul S, Gautier S, Auffret M, et al. Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol. 2015;25:1631–6.CrossRefPubMed Rolland B, Labreuche J, Duhamel A, Deheul S, Gautier S, Auffret M, et al. Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol. 2015;25:1631–6.CrossRefPubMed
16.
go back to reference Rolland B, Valin T, Langlois C, Auffret M, Gautier S, Deheul S, et al. Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. Int Clin Psychopharmacol. 2015;30:49–53.CrossRefPubMed Rolland B, Valin T, Langlois C, Auffret M, Gautier S, Deheul S, et al. Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. Int Clin Psychopharmacol. 2015;30:49–53.CrossRefPubMed
17.
go back to reference Bence C, Cottencin O, Deheul S, Gautier S, Bordet R, Rolland B. Baclofen-induced edema in alcohol use disorders. J Clin Pharmacol. 2014;54:478–81.CrossRefPubMed Bence C, Cottencin O, Deheul S, Gautier S, Bordet R, Rolland B. Baclofen-induced edema in alcohol use disorders. J Clin Pharmacol. 2014;54:478–81.CrossRefPubMed
18.
go back to reference Rolland B, Jaillette E, Carton L, Bence C, Deheul S, Saulnier F, et al. Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder. J Clin Psychopharmacol. 2014;34:153–6.CrossRefPubMed Rolland B, Jaillette E, Carton L, Bence C, Deheul S, Saulnier F, et al. Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder. J Clin Psychopharmacol. 2014;34:153–6.CrossRefPubMed
19.
go back to reference Auffret M, Rolland B, Deheul S, Loche V, Hennaux C, Cottencin O, et al. Severe tinnitus induced by off-label baclofen. Ann Pharmacother. 2014;48:656–9.CrossRefPubMed Auffret M, Rolland B, Deheul S, Loche V, Hennaux C, Cottencin O, et al. Severe tinnitus induced by off-label baclofen. Ann Pharmacother. 2014;48:656–9.CrossRefPubMed
20.
go back to reference Geoffroy PA, Auffret M, Deheul S, Bordet R, Cottencin O, Rolland B. Baclofen-induced manic symptoms: case report and systematic review. Psychosomatics. 2014;55:326–32.CrossRefPubMed Geoffroy PA, Auffret M, Deheul S, Bordet R, Cottencin O, Rolland B. Baclofen-induced manic symptoms: case report and systematic review. Psychosomatics. 2014;55:326–32.CrossRefPubMed
21.
go back to reference Rolland B, Auffret M, Franchitto N. Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment. Expert Opin Drug Saf. 2016;15:1–5.CrossRef Rolland B, Auffret M, Franchitto N. Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment. Expert Opin Drug Saf. 2016;15:1–5.CrossRef
22.
go back to reference Gerlach M, Egberts K, Dang S-Y, Plener P, Taurines R, Mehler-Wex C, et al. Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry. Expert Opin Drug Saf. 2016;15:1477–82.CrossRefPubMed Gerlach M, Egberts K, Dang S-Y, Plener P, Taurines R, Mehler-Wex C, et al. Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry. Expert Opin Drug Saf. 2016;15:1477–82.CrossRefPubMed
Metadata
Title
Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France
Authors
Marine Auffret
Julien Labreuche
Alain Duhamel
Sylvie Deheul
Olivier Cottencin
Régis Bordet
Sophie Gautier
Benjamin Rolland
Publication date
01-03-2017
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 3/2017
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-016-0489-7

Other articles of this Issue 3/2017

Drug Safety 3/2017 Go to the issue